

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1641

In re Patent Application of

LANG et al.

Serial No. 09/831,019

FEB 28 2003

Filed: May 4, 2001

Title: METHOD FOR DETECTING AND PURIFYING TCD8+ LYMPHOCYTE
POPULATIONS, SPECIFIC OF PEPTIDES PRESENT IN THE CONTEXT OF HLA

Assistant Commissioner for Patents

Washington, DC 20231

Atty Dkt. 1721-27

C# M#

Group Art Unit: 1641

Examiner: GABEL, G.

Date: February 28, 2003

RECEIVED
MAR 05 2003

TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00

\$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00

\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)

\$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)

\$ 0.00

Terminal disclaimer enclosed, add \$ 110.00

\$ 0.00

First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)

\$ 0.00

Please enter the previously unentered , filed

Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract

Applicant claims "small entity" status. Statement filed herewith

-\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

\$ 0.00

Assignment Recording Fee (\$40.00)

\$ 0.00

Other: Amendment; Copy of Notice to Comply (1/30/03); Statement; Paper and Computer Readable
Copies of Sequence Listing

0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:plb

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: B. J. Sadoff

COPIE
FEB 28 2003
PATENT

Notice to Comply

Application No.
09/831,019

Applicant(s)
LANG et al.

Examiner
Gailene R. Gabel

Art Unit
1641

Paper No. 8

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: Please note the sequences in page 10 of the specification.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact **RECEIVED**

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software.....703-306-2600

MAR 05 2003

TECH CENTER 1600/2900

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY